Fresh Tracks Therapeutics, Inc.
DelistedCIK 819050fmd_053DWQZ4TBVA7SKDD5WE2TMPNPManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Dec 31, 2023, 56 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 21 | 15 | 14 | 2 | 8 | 2 | 0 | 7 | 8 |
| Research and development | 11 | 11 | 10 | 14 | 13 | 20 | 11 | 28 | 14 | 3 |
| Total operating expenses | 32 | 30 | – | – | 19 | 32 | 23 | 41 | 28 | 14 |
| Operating income | (17) | (9) | (9) | (13) | (8) | (24) | (21) | (40) | (22) | (6) |
| Interest expense | – | – | – | – | 1 | 2 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 3 | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Net income | (16) | (9) | (9) | (13) | (9) | (24) | (21) | (39) | (21) | (6) |
| Net income to common shareholders | – | – | – | – | (15) | (14) | (21) | – | (21) | (6) |